Mandy Lauw: Can Reduced-Dose DOACs Be Applied to All Patients With VTE?
Mandy Lauw, Internist-hematologist at Erasmus MC, shared a post on LinkedIn about a recent article she and her colleagues co-authored, adding:
“Evidence for the efficacy and safety of doac dose-reduction for extended VTE treatment is substantial with the renove, eve and api-cat trials. But does this apply to all patients?
This short narrative review in HemaSphere Journal, written together with Marc Carrier and Saskia Middeldorp, provides some relevant insights for clinicians whether reduced-dose doacs can be uniformly applied to all patients with thrombosis and an indication for long-term anticoagulation.”
Title: Extended treatment for venous thromboembolism: Is direct oral anticoagulant dose-reduction better for all?
Authors: Mandy N. Lauw, Saskia Middeldorp, Marc Carrier
Read the Full Article on HemaSphere Journal
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 21, 2026, 09:52Afreenish Tasadaq: Contributing to Awareness about Bleeding Disorders
-
Sep 21, 2026, 08:49Andrea Bridges: When Support Becomes a Commitment to Give Back
-
Sep 21, 2026, 08:21Managing Thrombotic Risk in Pregnancy
-
Sep 21, 2026, 04:06Allison Lewin: How Gender Shapes the Way We Receive Medical Care
-
Sep 21, 2026, 03:49Jessica Lee: Walking Together for a Stronger Bleeding Disorders Community
-
Sep 21, 2026, 03:36Syed Asif Ali Shah: From Pakistan to Australia – A Clinical Haematology Milestone
-
Sep 21, 2026, 03:22Katie Baca-Motes: Estradiol Fluctuations May Help Explain Menstrual Migraine
-
Sep 21, 2026, 03:00Family History Can Reveal Hidden Risk of Aortic Dissection – The Marfan Foundation
-
Sep 21, 2026, 02:47Transitioning from Paediatric to Adult Haemophilia Care – Haemophilia Foundation Australia